Table 2.
Treatment effect
| Measurements | Group | Baseline/before IFN-beta administration median [range] resp. mean (s.d.) | After 8 days of IFN-beta administration median [range] resp. mean (s.d.) | Statistic (paired t-test) | df | p Value |
|---|---|---|---|---|---|---|
| STAI | Total Avonex Rebif |
30 [25–48] 27.5 [25–40] 32 [26–48] |
29 [22–43] 27.5 [22–40] 31 [27–43] |
0.69077 0.31399 0.59628 |
16 7 8 |
n.s. n.s. n.s. |
| HDRS | Total Avonex Rebif |
0 [0–3] 0 [0–2] 1 [0–3] |
2 [0–13] 0.5 [0–4] 6 [0–13] |
−3.5193− 1.4331− 3.8733 |
16 7 8 |
0.0028 n.s. 0.0047 |
| Body temperature | Total Avonex Rebif |
36.7° (±0.3°) 36.7° (±0.3°) 36.7° (±0.3°) |
38.7° (±0.4°) 38.6° (±0.5°) 38.8° (±0.4°) |
−16.914− 9.7879− 15.222 |
16 7 8 |
<0.0001 <0.0001 <0.0001 |
| Baseline/before IFN-beta administration mean (s.d.) |
6 hours after first IFN-administration mean (s.d.) |
|||||
| CXCL10 (in ng/ml) |
Total Avonex Rebif |
143.0 (±79.0) 179.9 (±82.9) 110.2 (±62.5) |
4543.6 (±1680.6) 3575.1 (±1302.3) 5404.5 (±1546.9) |
−10.798− 7.4862− 10.479 |
16 7 8 |
<0.0001 0.0001 <0.0001 |